Conference 2019 - 'The next negotiation'Monday, 20 May 2019, Sydney
PharmaDispatch 2019 will be held on Monday 20 May 2019 in the Ballroom at The Establishment Hotel in Sydney (252 George Street).
The one-day conference will focus on 'negotiation'.
How will the sector's different players be positioning their organisations and members in 2019? What are the opportunities, risks and drivers, and who will be the key influencers?
The Establishment Ballroom, on level 2, is a larger room that holds 300 people. Over 200 people have already registered for PharmaDispatch 2019.
There is a heavily discounted registration for patients and patient representative groups. Please contact email@example.com for more information.
The event opens for registration at 8am with tea, coffee and other refreshments.
The conference is based on mediated panel discussions without any formal presentations. It is timed for the period around or more likely immediately following the federal election.
The 2019 federal election - what now?
The conference will start with two discussions about the outcome of the 18 May election.
One discussion will involve the leaders of some of the health sector's key representative groups, including Liz de Somer from Medicines Australia, the Pharmacy Guild's Pam Price, AusBiotech's Lorraine Chiroiu, Dr Rachel David from Private Healthcare Australia and Ian Burgess of the Medical Technology Association of Australia.
Professor Andrew Wilson
A 1:1 discussion with the chair of the Pharmaceutical Benefits Advisory Committee.
Trade agreements and negotiation - past, present and future (Sponsor: Medicines Australia)
The panel will focus on trade and negotiations. It features Joseph Damond from US-based Bio, former senior US trade negotiator Barbara Weisel, and AstraZeneca's director of government affairs Kieran Schneemann.
The future of the pharmaceutical supply chain
A panel on the future of the pharmaceutical supply chain featuring DHL's Saul Resnick, leading pharmacy compounder David Slade, Carlo Montagner from Specialised Therapeutics Australia, Symbion CEO Brett Barons and NostraData's Mike da Gama.
The future of the supply chain has become one of the most contentious areas of pharmaceutical policy with debate over exclusive direct distribution and the stalled reform of the payment system.
The market access challenge for emerging technologies (Sponsor: Health Technology Analysts)
A panel that will discuss the challenge of market access featuring Dr Colman Taylor of Health Technology Analysts; Greg Cook, associate director of market access strategy, policy and capability, Bristol-Myers Squibb; Richard Vines of Rare Cancers Australia; Bio's Joseph Damond; and Andrew Mitchell, senior adviser, technology, assessment and access division, Department of Health.
A panel of pharmaceutical sector leaders features AstraZeneca's Liz Chatwin, Merck's Leah Goodman, Andrew Carter of Commercial Eyes, Belinda Wood from the Pharmaceutical Society of Australia, and one of Australia's foremost experts on pharmacy Bruce Annabel.
They will discuss the future, how the environment is evolving and what we should now expect in the years ahead.
Cocktail event and event close